6XC Stock Overview
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Soleno Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.78 |
| 52 Week High | US$48.40 |
| 52 Week Low | US$3.43 |
| Beta | -1.54 |
| 1 Month Change | -7.40% |
| 3 Month Change | -16.39% |
| 1 Year Change | 829.95% |
| 3 Year Change | 164.99% |
| 5 Year Change | n/a |
| Change since IPO | 39.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6XC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | -0.3% |
| 1Y | 829.9% | -19.9% | 2.8% |
Return vs Industry: 6XC exceeded the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: 6XC exceeded the German Market which returned 2.8% over the past year.
Price Volatility
| 6XC volatility | |
|---|---|
| 6XC Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6XC's share price has been volatile over the past 3 months.
Volatility Over Time: 6XC's weekly volatility has decreased from 93% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 33 | Anish Bhatnagar | soleno.life |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. Fundamentals Summary
| 6XC fundamental statistics | |
|---|---|
| Market cap | €1.55b |
| Earnings (TTM) | -€36.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-42.9x
P/E RatioIs 6XC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6XC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$38.99m |
| Earnings | -US$38.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6XC perform over the long term?
See historical performance and comparison